carnitine has been researched along with Peripheral Vascular Diseases in 17 studies
Peripheral Vascular Diseases: Pathological processes involving any one of the BLOOD VESSELS in the vasculature outside the HEART.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We explored the efficacy of intravenous therapy with propionyl L-carnitine in patients with both peripheral arterial disease (PAD) and chronic renal insufficiency requiring haemodialysis." | 5.12 | A randomised, controlled clinical trial evaluating changes in therapeutic efficacy and oxidative parameters after treatment with propionyl L-carnitine in patients with peripheral arterial disease requiring haemodialysis. ( Celotta, G; Di Pino, L; Fallico, R; Fatuzzo, P; Ferrante, M; Massimiliano, A; Neri, S; Oliveri Conti, G; Pennisi, G; Rapisarda, F; Signorelli, SS, 2006) |
| " In addition, a decrease in dosage of oral antihyperglycaemic agents was observed in 21 patients at T1." | 2.71 | Effects of propionyl-carnitine in patients with type 2 diabetes and peripheral vascular disease: results of a pilot trial. ( Acerra, G; del Guercio, R; Fasano, C; Federico, P; Gioia, F; Madrid, E; Mattera, E; Ragozzino, G; Salomone, P, 2004) |
| " In conclusion, after chronic administration of PLC, a significant increment in skeletal muscle uptake of 99mTc-sestamibi was demonstrated without any apparent change in regional blood flow." | 2.68 | Technetium-99m sestamibi leg scintigraphy for non-invasive assessment of propionyl-L-carnitine induced changes in skeletal muscle metabolism. ( Azzena, G; Cittanti, C; Colamussi, P; Giganti, M; Manfrini, S; Orlandi, C; Piffanelli, A; Uccelli, L, 1997) |
| "L-carnitine has an important role in the metabolism of fatty acids." | 2.38 | New thoughts of pathophysiology and therapy of ischemic heart disease. ( Pepine, CJ, 1991) |
| " Long-term administration (4 weeks) of PLC (60 and 250 mg/kg os) caused a significant improvement of walking capacity throughout the entire period." | 1.29 | Effect of propionyl-L-carnitine in a rat model of peripheral arteriopathy: a functional, histologic, and NMR spectroscopic study. ( Arrigoni Martelli, E; Aureli, T; Conti, F; Corsico, N; Di Cocco, ME; Lucreziotti, MR; Miccheli, A; Nardone, A; Pesce, D; Spagnoli, LG, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 10 (58.82) | 18.2507 |
| 2000's | 7 (41.18) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andreozzi, GM | 1 |
| Ragozzino, G | 1 |
| Mattera, E | 1 |
| Madrid, E | 1 |
| Salomone, P | 1 |
| Fasano, C | 1 |
| Gioia, F | 1 |
| Acerra, G | 1 |
| del Guercio, R | 1 |
| Federico, P | 1 |
| Hiatt, WR | 1 |
| Carrero, JJ | 1 |
| Grimble, RF | 1 |
| Signorelli, SS | 2 |
| Fatuzzo, P | 2 |
| Rapisarda, F | 2 |
| Neri, S | 2 |
| Ferrante, M | 2 |
| Oliveri Conti, G | 2 |
| Fallico, R | 2 |
| Di Pino, L | 2 |
| Pennisi, G | 2 |
| Celotta, G | 2 |
| Massimiliano, A | 1 |
| Anzaldi, M | 1 |
| Sabbá, C | 1 |
| Berardi, E | 1 |
| Antonica, G | 1 |
| Ferraioli, G | 1 |
| Buonamico, P | 1 |
| Godi, L | 2 |
| Brevetti, G | 2 |
| Albano, O | 1 |
| Corsico, N | 1 |
| Nardone, A | 1 |
| Lucreziotti, MR | 1 |
| Spagnoli, LG | 1 |
| Pesce, D | 1 |
| Aureli, T | 2 |
| Di Cocco, ME | 1 |
| Miccheli, A | 2 |
| Conti, F | 2 |
| Arrigoni Martelli, E | 1 |
| Isner, JM | 1 |
| Rosenfield, K | 1 |
| Timmons, JA | 1 |
| Poucher, SM | 1 |
| Constantin-Teodosiu, D | 1 |
| Worrall, V | 1 |
| Macdonald, IA | 1 |
| Greenhaff, PL | 1 |
| Bolognesi, M | 1 |
| Amodio, P | 1 |
| Merkel, C | 1 |
| Gatta, A | 1 |
| Persico, G | 1 |
| Amato, B | 1 |
| Aprea, G | 1 |
| Cerfolio, P | 1 |
| Markabaoui, AK | 1 |
| Cittanti, C | 1 |
| Colamussi, P | 1 |
| Giganti, M | 1 |
| Orlandi, C | 1 |
| Uccelli, L | 1 |
| Manfrini, S | 1 |
| Azzena, G | 1 |
| Piffanelli, A | 1 |
| Di Marzo, L | 1 |
| Sapienza, P | 1 |
| Tedesco, M | 1 |
| Mingoli, A | 1 |
| Capuani, G | 1 |
| Giuliani, A | 1 |
| Cavallaro, A | 1 |
| Barker, GA | 1 |
| Green, S | 1 |
| Askew, CD | 1 |
| Green, AA | 1 |
| Walker, PJ | 1 |
| Pepine, CJ | 1 |
| Angelini, C | 1 |
| Rosa, M | 1 |
| Carrozzo, R | 1 |
| Perna, S | 1 |
| Corsi, M | 1 |
| Matarazzo, A | 1 |
| Marcialis, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The THOR IDE Study[NCT05916950] | 155 participants (Anticipated) | Interventional | 2023-08-31 | Not yet recruiting | |||
| Multicenter, Randomized, Dose-search, Parallel, Double-blind, and Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of Intramuscular Administration of Allogeneic Adipose Tissue Adult Mesenchymal Stem Cells in Diabetic Patients With Cri[NCT04466007] | Phase 2 | 90 participants (Anticipated) | Interventional | 2021-01-11 | Active, not recruiting | ||
| Evaluation of Cilostazol in Combination With L-Carnitine in Subjects With Intermittent Claudication[NCT00822172] | Phase 4 | 164 participants (Actual) | Interventional | 2008-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. The time during the conduct of the exercise treadmill test at which the subject first reported claudication symptoms is referred to as the claudication onset time (COT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed. (NCT00822172)
Timeframe: Baseline, Day 180
| Intervention | Log Minutes (Mean) |
|---|---|
| Cilostazol + L-Carnitine | 1.065 |
| Cilostazol + Placebo | 0.896 |
Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. The time during the conduct of the exercise treadmill test at which the subject first reported claudication symptoms is referred to as the claudication onset time (COT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed. (NCT00822172)
Timeframe: Baseline, Day 90
| Intervention | Log Minutes (Mean) |
|---|---|
| Cilostazol + L-Carnitine | 1.001 |
| Cilostazol + Placebo | 0.815 |
Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. This maximum time walked is referred to as the peak walking time (PWT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed. (NCT00822172)
Timeframe: Baseline, Day 180
| Intervention | Log Minutes (Mean) |
|---|---|
| Cilostazol + L-Carnitine | 0.241 |
| Cilostazol + Placebo | 0.134 |
Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. This maximum time walked is referred to as the peak walking time (PWT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed. (NCT00822172)
Timeframe: Baseline, Day 180
| Intervention | Log Minutes (Mean) |
|---|---|
| Cilostazol + L-Carnitine | 0.267 |
| Cilostazol + Placebo | 0.145 |
Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. This maximum time walked is referred to as the peak walking time (PWT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed. (NCT00822172)
Timeframe: Baseline, Day 90
| Intervention | Log Minutes (Mean) |
|---|---|
| Cilostazol + L-Carnitine | 0.166 |
| Cilostazol + Placebo | 0.139 |
Subjects completed the Walking Impairment Questionnaire (WIQ) whereby they were asked about their maximal walking distance before having to rest as a result of claudication symptoms associated with their peripheral artery disease (PAD). The WIQ was administered at the Baseline, Day 90, and Day 180 visits. On the WIQ subjects were asked a series of questions related to their degree of physical difficulty that best described how hard it was for the subject to walk on level ground without stopping to rest. The questions began by asking the degree of difficulty walking around indoors, then 50 feet, 150 feet, 300 feet, 600 feet, 900 feet, and lastly 1500 feet. The responses range from None (best outcome) to Slight, then Some, then Much, then lastly Unable (worst outcome). The walking distance score was calculated from the 7 questions in the section by way of a weighted sum. A score of 100 indicated no walking impairment. A score of 0 corresponded to the highest degree of walking impairment (NCT00822172)
Timeframe: Baseline, Day 180
| Intervention | score on a scale (Mean) |
|---|---|
| Cilostazol + L-Carnitine | 13.20 |
| Cilostazol + Placebo | 6.57 |
Subjects completed the Walking Impairment Questionnaire (WIQ) whereby they were asked about their maximal walking distance before having to rest as a result of claudication symptoms associated with their peripheral artery disease (PAD). The WIQ was administered at the Baseline, Day 90, and Day 180 visits. On the WIQ subjects were asked a series of questions related to their degree of physical difficulty that best described how hard it was for the subject to walk on level ground without stopping to rest. The questions began by asking the degree of difficulty walking around indoors, then 50 feet, 150 feet, 300 feet, 600 feet, 900 feet, and lastly 1500 feet. The responses range from None (best outcome) to Slight, then Some, then Much, then lastly Unable (worst outcome). The walking distance score was calculated from the 7 questions in the section by way of a weighted sum. A score of 100 indicated no walking impairment. A score of 0 corresponded to the highest degree of walking impairment (NCT00822172)
Timeframe: Baseline, Day 90
| Intervention | score on a scale (Mean) |
|---|---|
| Cilostazol + L-Carnitine | 12.98 |
| Cilostazol + Placebo | 10.01 |
5 reviews available for carnitine and Peripheral Vascular Diseases
| Article | Year |
|---|---|
Propionyl l-carnitine: intermittent claudication and peripheral arterial disease.
Topics: Cardiotonic Agents; Carnitine; Exercise; Humans; Intermittent Claudication; Peripheral Vascular Dise | 2009 |
Treatment of disability in peripheral arterial disease: new drugs.
Topics: Arteriosclerosis; Carnitine; Clinical Trials as Topic; Exercise Therapy; Humans; Hypolipidemic Agent | 2004 |
Does nutrition have a role in peripheral vascular disease?
Topics: Antioxidants; Ascorbic Acid; Atherosclerosis; Carnitine; Dietary Fats, Unsaturated; Dietary Fiber; F | 2006 |
Redefining the treatment of peripheral artery disease. Role of percutaneous revascularization.
Topics: Angioplasty, Balloon; Angioplasty, Balloon, Laser-Assisted; Angioplasty, Laser; Arterial Occlusive D | 1993 |
Redefining the treatment of peripheral artery disease. Role of percutaneous revascularization.
Topics: Angioplasty, Balloon; Angioplasty, Balloon, Laser-Assisted; Angioplasty, Laser; Arterial Occlusive D | 1993 |
Redefining the treatment of peripheral artery disease. Role of percutaneous revascularization.
Topics: Angioplasty, Balloon; Angioplasty, Balloon, Laser-Assisted; Angioplasty, Laser; Arterial Occlusive D | 1993 |
Redefining the treatment of peripheral artery disease. Role of percutaneous revascularization.
Topics: Angioplasty, Balloon; Angioplasty, Balloon, Laser-Assisted; Angioplasty, Laser; Arterial Occlusive D | 1993 |
New thoughts of pathophysiology and therapy of ischemic heart disease.
Topics: Animals; Carnitine; Heart; Heart Failure; Humans; Myocardial Infarction; Myocardial Ischemia; Myocar | 1991 |
9 trials available for carnitine and Peripheral Vascular Diseases
| Article | Year |
|---|---|
Effects of propionyl-carnitine in patients with type 2 diabetes and peripheral vascular disease: results of a pilot trial.
Topics: Blood Glucose; Carnitine; Diabetes Mellitus, Type 2; Female; Humans; Injections, Intravenous; Male; | 2004 |
A randomised, controlled clinical trial evaluating changes in therapeutic efficacy and oxidative parameters after treatment with propionyl L-carnitine in patients with peripheral arterial disease requiring haemodialysis.
Topics: Aged; Aldehydes; Carnitine; Double-Blind Method; Humans; Malondialdehyde; Middle Aged; Nitrates; Nit | 2006 |
Propionyl-L-carnitine therapy: effects on endothelin-1 and homocysteine levels in patients with peripheral arterial disease and end-stage renal disease.
Topics: Ankle; Branchial Region; Carnitine; Double-Blind Method; Endothelin-1; Homocysteine; Humans; Infusio | 2006 |
Comparison between the effect of L-propionylcarnitine, L-acetylcarnitine and nitroglycerin in chronic peripheral arterial disease: a haemodynamic double blind echo-Doppler study.
Topics: Acetylcarnitine; Blood Flow Velocity; Cardiotonic Agents; Carnitine; Child, Preschool; Cross-Over St | 1994 |
Effect of 8-day therapy with propionyl-L-carnitine on muscular and subcutaneous blood flow of the lower limbs in patients with peripheral arterial disease.
Topics: Administration, Oral; Adolescent; Adult; Aged; Arteries; Blood Flow Velocity; Carnitine; Humans; Mid | 1995 |
The early effects of intravenous L-propionyl carnitine on ulcerative trophic lesions of the lower limbs in arteriopathic patients: a controlled randomized study.
Topics: Aged; Aged, 80 and over; Amputation, Surgical; Anti-Inflammatory Agents, Non-Steroidal; Arterial Occ | 1995 |
Technetium-99m sestamibi leg scintigraphy for non-invasive assessment of propionyl-L-carnitine induced changes in skeletal muscle metabolism.
Topics: Arterial Occlusive Diseases; Carnitine; Female; Humans; Leg; Male; Middle Aged; Muscle, Skeletal; Pe | 1997 |
31Phosphorus magnetic resonance spectroscopy to evaluate medical therapy efficacy in peripheral arterial disease. A pilot study.
Topics: Aged; Animals; Carnitine; Double-Blind Method; Humans; Magnetic Resonance Imaging; Male; Middle Aged | 1999 |
Effect of propionyl-L-carnitine on exercise performance in peripheral arterial disease.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Carnitine; Exercise; Female | 2001 |
3 other studies available for carnitine and Peripheral Vascular Diseases
| Article | Year |
|---|---|
Effect of propionyl-L-carnitine in a rat model of peripheral arteriopathy: a functional, histologic, and NMR spectroscopic study.
Topics: Animals; Cardiotonic Agents; Carnitine; Disease Models, Animal; Energy Metabolism; Femoral Artery; H | 1993 |
Increased acetyl group availability enhances contractile function of canine skeletal muscle during ischemia.
Topics: Acetylcarnitine; Adenosine Triphosphate; Aerobiosis; Anaerobiosis; Animals; Carbohydrate Metabolism; | 1996 |
Muscle carnitine deficiency in patients with severe peripheral vascular disease.
Topics: Aged; Carnitine; Carnitine O-Acetyltransferase; Carnitine O-Palmitoyltransferase; Humans; Ischemia; | 1991 |